Virginia Kaklamani, MD, DSc

Type of Cancer

Breast

ClinicalTrials.gov Identifier

ClinicalTrials.gov registration not required

Principal Investigator

Virginia Kaklamani, MD, DSc

Patient data acquisition and analysis approaches maximizing search for biomarkers considering clinical diagnostic diversity and genetic and epigenetic influence (CTMS# 22-0069)

This is a translational clinical study aiming to develop approaches to process effectively human tissues and identify biomarkers for painful and non-painful chemotherapy-induced peripheral neuropathy (CIPN). This study will involve obtaining two skin biopsies representing affected and non-affected parts of each patient’s limb. Painful and non-painful neuropathies will be determined by a variety…

Type of Cancer

Breast

ClinicalTrials.gov Identifier

ClinicalTrials.gov registration not required

Principal Investigator

Virginia Kaklamani, MD, DSc

EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk

A Study of imlunestrant vs physician’s choice endocrine therapy as adjuvant treatment after 2 to 5 years of standard adjuvant endocrine therapy for patients with ER+, HER2- early breast cancer with an increased risk of recurrence

ClinicalTrials.gov Identifier

ClinicalTrials.gov registration not required

Principal Investigator

Virginia Kaklamani, MD, DSc

A Pre-Surgical Window of Opportunity Trial Investigating the Effect of Cyclosporin A on Triple Negative Breast Cancer with Defective DNA Repair

This will be a single arm, non-randomized, pre-surgical clinical trial of women with newly diagnosed triple negative breast cancer with high g-H2Ax comparing changes in biomarkers from a diagnostic core needle biopsy to surgical pathology specimen or repeat core needle biopsy.

ClinicalTrials.gov Identifier

ClinicalTrials.gov registration not required

Principal Investigator

Virginia Kaklamani, MD, DSc

A Phase 2, Randomized, Active-controlled, Open-label, Multicenter Study of Belzutifan Plus Fulvestrant in Participants With Estrogen Receptor Positive, HER2 Negative Unresectable Locally Advanced or Metastatic Breast Cancer After Progression on Previous

This is a Phase 2, randomized, active-controlled, parallel-group, multisite, open-label studyof belzutifan plus fulvestrant versus everolimus plus ETPC (fulvestrant or exemestane) inparticipants with ER+/HER2- unresectable, locally advanced, or mBC.

ClinicalTrials.gov Identifier

ClinicalTrials.gov registration not required

Principal Investigator

Virginia Kaklamani, MD, DSc

Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence—A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)

This is a Phase 3, global, multicenter, randomized, open-label study.

ClinicalTrials.gov Identifier

ClinicalTrials.gov registration not required

Principal Investigator

Virginia Kaklamani, MD, DSc

A Phase 1a/1b Study of the PI3a:RSS Breaker BBO-10203 in Subjects with Advanced Solid Tumors (The BREAKER-101 Trial)

First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with trastuzumab in patients with advanced solid tumors.

About Virginia Kaklamani, MD, DSc

Gender

Languages Spoken

Breast Cancer is a disease we all need to fight together

Credentials

Positions

Certifications

Education

Locations & Contact

Zeller Building

29.5130016, -98.5806009

Dr. Kaklamani is very, very knowledgeable, very polite. She makes you feel comfortable in the office talking about difficult topics. I would highly recommend her and appreciate her greatly. Thank you.

Research & Publications

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

BRCA 1/2 gene mutation and gastrointestinal stromal tumours: a potential association

National comprehensive cancer network. Genetic/familial high-risk assessment: breast and ovarian, version 1.2014.

Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579)

View All Publications — Virginia Kaklamani

Clinical Trials

Patient data acquisition and analysis approaches maximizing search for biomarkers considering clinical diagnostic diversity and genetic and epigenetic influence (CTMS# 22-0069)

EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk

A Pre-Surgical Window of Opportunity Trial Investigating the Effect of Cyclosporin A on Triple Negative Breast Cancer with Defective DNA Repair

A Phase 2, Randomized, Active-controlled, Open-label, Multicenter Study of Belzutifan Plus Fulvestrant in Participants With Estrogen Receptor Positive, HER2 Negative Unresectable Locally Advanced or Metastatic Breast Cancer After Progression on Previous

Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence—A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)

A Phase 1a/1b Study of the PI3a:RSS Breaker BBO-10203 in Subjects with Advanced Solid Tumors (The BREAKER-101 Trial)